To include your compound in the COVID-19 Resource Center, submit it here.

Chiesi licenses Protalix's Fabry's disease candidate

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) granted Chiesi Farmaceutici S.p.A. (Parma, Italy)

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE